Article Text
Abstract
After completing my neurological training my main field of interest was in cerebrovascular disorders. However, my practice changed in several ways in 1982 after I gave intravenous immunoglobulin (IVIg) to a 16-year-old boy with chronic inflammatory demyelinating polyneuropathy (CIDP) and he improved. Similar patients started to be referred to me and I began to see many types of peripheral neuropathy and so learned a lot about diseases of the peripheral nervous system in general, and the diagnostic strategies required to sort them out. That first patient undoubtedly had an impact on my whole neurological practice.
He had been admitted with a 2-month history of progressive weakness in his arms and legs, which became paralysed. There were no tendon reflexes apart from one depressed ankle reflex. There were no sensory signs, although he had some tingling in the hands and feet. Nerve conduction velocities were somewhat slow: 40 m/s in the
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- A nationwide survey of combined central and peripheral demyelination in Japan
- Chronic inflammatory demyelinating polyneuropathy and pregnancy: systematic review
- Chronic inflammatory demyelinating polyneuropathy: a rare cause of falls
- Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment
- Electrodiagnostic data-driven clustering identifies a prognostically different subgroup of patients with chronic inflammatory demyelinating polyneuropathy
- Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin
- Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases
- Visual disturbance in a patient with progressive limb weakness
- Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy
- Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up